Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Promise of Pharmacogenomics in Reducing Toxicity during Acute Lymphoblastic Leukemia Maintenance Treatment

1 Apr 2017

Abstract excerpt

Pediatric acute lymphoblastic leukemia (ALL) affects a substantial number of children every year and requires a long and rigorous course of chemotherapy treatments in three stages, with the longest phase, the maintenance phase, lasting 2-3years. While the primary drugs used in the maintenance phase, 6-mercaptopurine (6-MP) and methotrexate (MTX), are necessary for decreasing risk of relapse, they also have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Childhood Cancer Survivors' Quality of Life
Share to Renal Transplantation Outcomes and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28391009
DOI: 10.1016/j.gpb.2016.11.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Promise of Pharmacogenomics in Reducing Toxicity during Acute Lymphoblastic Leukemia Maintenance TreatmentPMID 28391009Read ↗

NUDT15 Pharmacogenetics in Acute Lymphoblastic Leukemia: Synthesizing Progress for Personalized Thiopurine TherapySemantic proximity Read ↗

Pharmacogenomic Markers of Methotrexate Response in the Consolidation Phase of Pediatric Acute Lymphoblastic Leukemia Treatment.Semantic proximity Read ↗

Implementation of Pharmacogenetics to Individualize Treatment Regimens for Children with Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

ITPA, TPMT, and NUDT15 Genetic Polymorphisms Predict 6-Mercaptopurine Toxicity in Middle Eastern Children With Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia.Semantic proximity Read ↗

Pharmacogenetics of Childhood Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Methotrexate Disposition in Pediatric Patients with Acute Lymphoblastic Leukemia: What Have We Learnt From the Genetic Variants of Drug TransportersSemantic proximity Read ↗

Pediatric Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Pharmacogenetic considerations for acute lymphoblastic leukemia therapies.Semantic proximity Read ↗

Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia.Semantic proximity Read ↗

Association of NUDT15*3 and FPGS 2572C>T Variants with the Risk of Early Hematologic Toxicity During 6-MP and Low-Dose Methotrexate-Based Maintenance Therapy in Indian Patients with Acute Lymphoblastic Leukemia.Semantic proximity Read ↗

Pharmacogenetics of Childhood Acute Lymphoblastic Leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.